ScottAntoniaMD

Department Chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center Professor of Oncologic Sciences at the University of South Florida College of Medicine

Join to view full profile

Dr. Antonia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Antonia's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
Mdc 44
Tampa, FL 33612
Phone+1 813-745-4673

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Yale-New Haven Medical Center (St. Raphael)Residency, Internal Medicine, 1989 - 1991
Yale-New Haven Medical CenterInternship, Internal Medicine, 1989 - 1990
Uconn School Of MedicineClass of 1989

Certifications & Licensure

NC State Medical License 2018 - 2025
FL State Medical License 1995 - 2020
CT State Medical License 1991 - 1995
WI State Medical License 1990 - 1991
American Board of Internal Medicine Medical Oncology

Clinical Trials

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Start of enrollment: 2023 May 16
Recruiting
Phase 2
Roles: Contact

Publications & Presentations

PubMed

69 citations
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
Scott J. Antonia, Ani Sarkis Balmanoukian, Julie R. Brahmer, Sai-Hong Ignatius Ou, Matthew D. Hellmann
Journal of Thoracic Oncology. 2019-10-01
419 citations
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinic...
Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft
JAMA Oncology. 2020-05-01
65 citations
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Neil H. Segal, Sai-Hong Ignatius Ou, Ani Sarkis Balmanoukian, Matthew G. Fury, Erminia Massarelli
European Journal of Cancer. 2019-03-01

Press Mentions

Developing New Tools to Fight CancerOctober 17th, 2022
Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory BoardJune 8th, 2022
Immutep Appoints Leading Oncologists to Its Clinical Advisory BoardMay 18th, 2022
Join now to see all